...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Lophius Biosciences Launches Interactive T CELL TOOLS Product Finder and Online Order Portal

| Print |
Wednesday, 16 July 2014 10:00 (UTC + 2)

lophius logo neu

Regensburg, Germany, July 16, 2014 / B3C newswire / – Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostic systems for functional assessment of pathogen/disease-reactive T cells, today announced the launch of its new T CELL TOOLS product line together with its new e-commerce online order portal. The new web based customer interface at www.Lophius.com has been designed to provide an intuitive product selection and online order platform accelerating the ability of customers to quickly identify and select products from Lophius’ continuously growing portfolio.

T CELL TOOLS comprise selected research reagents to allow easy and reliable T cell stimulation as well as robust quantification and monitoring of cell mediated immune responses (CMI). Different antigens from various pathogens with a current focus on the human cytomegalovirus (HCMV) and Epstein-Barr Virus (EBV) are well coordinated and validated to jointly contribute to a standardized and reliable read-out system. Hence, the individual product modules of T CELL TOOLS offer modular and complementary solutions for optimal assay performance.

Today, T CELL TOOLS include, amongst, peptide pools, lysates an proteins, a panel of T-activated antigens - complete proteins that are formulated using Lophius’ proprietary T-activation technology platform facilitating uptake and processing of the proteins via the canonical MHC class-I cross-presentation pathway. As a result, clinically relevant effector cells of the CMI such as CD4- and CD8-positve T cells as well as NK, and NKT cells will be activated. Optionally, customers may also combine their antigens with a matching IFN-gamma ELISPOT T-Track® basic kit to reach maximum sensitivity and specificity upon measuring pathogen specific T cells.

Lophius aims to quickly expand the panel of antigens, antibodies, conjugates and read-out options to offer its customers a very comprehensive panel of relevant and well coordinated tools in near future to booster T cell research. Customers include researchers and clinicians in the field of immunology, infectious diseases, transplantation, clinical virology, oncology, autoimmune diseases, gynecology, and intensive care who need optimal performance by using either the standardized in-vitro diagnostic kit T-Track® CMV or an individually compiled T cell activity assay based on the robust T-Track® technology.

“We are very excited to announce the launch of our e-commerce portal as we believe it will provide our customers greater access to Lophius’ products at their convenience,” said Dr. Robert Phelps, CEO of Lophius Biosciences. “With our intuitive product finder, consumers can browse and order some of the most innovative T cell products on the market” added Prof. Ralf Wagner, Chairman of the Board.


About Lophius Biosciences
Lophius Biosciences GmbH, a German biotech company, is focusing on the development and marketing of innovative T cell based diagnostic systems for diagnosis and immunomonitoring. The Company’s flag ship product is T-Track® CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo an immunosuppressive therapy. With its innovative products, the Company aims to significantly improve therapy control and personalized treatment of patients in the area of transplantation medicine, infectious and autoimmune diseases.


Contact

Dr. Robert Phelps, CEO
Lophius Biosciences GmbH
Josef-Engert-Str. 13
93053 Regensburg, Germany
Tel +49 (0)941 63091970                
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.Lophius.com